Serum amyloid a protein concentrations in patients with familial Mediterranean fever
AIM: the determination of serum amyloid A (SAA) protein concentrations in FMF patients: the colchicine-resistant patients and the patients responded to the different doses of colchicine, and estimation of the risk of the amyloidosis development in these patients. SAA concentration was measured in 58 FMF patients: 23 colchicine-resistant patients without amyloidosis and 35 patients responded to the different doses of colchicine also without amyloidosis as a group of comparison. Serum SAA concentration was measured by ELISA (Enzyme Linked-Immuno-Sorbent-Assay) method using "ANOGEN" kit (Canada). Serum SAA concentration was the same in both groups of the patients: colchicine-resistant patients and patients responded to the different doses of colchicine. The findings of our study indicate that the risk of the amyloidosis development is the same in colchicine-resistant patients and patients responded to the different doses of colchicine.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2011 |
|---|---|
| Erschienen: |
2011 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2011 |
|---|---|
| Enthalten in: |
Georgian medical news - (2011), 201 vom: 15. Dez., Seite 48-51 |
| Sprache: |
Russisch |
|---|
| Beteiligte Personen: |
Dzhndoian, Z T [VerfasserIn] |
|---|
| Themen: |
Biomarkers, Pharmacological |
|---|
| Anmerkungen: |
Date Completed 01.08.2012 Date Revised 21.11.2013 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM21514953X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM21514953X | ||
| 003 | DE-627 | ||
| 005 | 20231224024949.0 | ||
| 007 | tu | ||
| 008 | 231224s2011 xx ||||| 00| ||rus c | ||
| 028 | 5 | 2 | |a pubmed24n0717.xml |
| 035 | |a (DE-627)NLM21514953X | ||
| 035 | |a (NLM)22306501 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 100 | 1 | |a Dzhndoian, Z T |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Serum amyloid a protein concentrations in patients with familial Mediterranean fever |
| 264 | 1 | |c 2011 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 01.08.2012 | ||
| 500 | |a Date Revised 21.11.2013 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a AIM: the determination of serum amyloid A (SAA) protein concentrations in FMF patients: the colchicine-resistant patients and the patients responded to the different doses of colchicine, and estimation of the risk of the amyloidosis development in these patients. SAA concentration was measured in 58 FMF patients: 23 colchicine-resistant patients without amyloidosis and 35 patients responded to the different doses of colchicine also without amyloidosis as a group of comparison. Serum SAA concentration was measured by ELISA (Enzyme Linked-Immuno-Sorbent-Assay) method using "ANOGEN" kit (Canada). Serum SAA concentration was the same in both groups of the patients: colchicine-resistant patients and patients responded to the different doses of colchicine. The findings of our study indicate that the risk of the amyloidosis development is the same in colchicine-resistant patients and patients responded to the different doses of colchicine | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Biomarkers, Pharmacological |2 NLM | |
| 650 | 7 | |a Serum Amyloid A Protein |2 NLM | |
| 650 | 7 | |a Colchicine |2 NLM | |
| 650 | 7 | |a SML2Y3J35T |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Georgian medical news |d 2005 |g (2011), 201 vom: 15. Dez., Seite 48-51 |w (DE-627)NLM154716634 |x 1512-0112 |7 nnns |
| 773 | 1 | 8 | |g year:2011 |g number:201 |g day:15 |g month:12 |g pages:48-51 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2011 |e 201 |b 15 |c 12 |h 48-51 | ||